Literature DB >> 22077553

Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Karl Staser1, Feng-Chun Yang, D Wade Clapp.   

Abstract

Neurofibromatosis type 1 (NF1) is a genetic disease that results from either heritable or spontaneous autosomal dominant mutations in the NF1 gene. A second-hit mutation precedes the predominant NF1 neoplasms, which include myeloid leukemia, optic glioma, and plexiform neurofibroma. Despite this requisite NF1 loss of heterozygosity in the tumor cell of origin, nontumorigenic cells contribute to both generalized and specific disease manifestations. In mouse models of plexiform neurofibroma formation, Nf1 haploinsufficient mast cells promote inflammation, accelerating tumor formation and growth. These recruited mast cells, hematopoietic effector cells long known to permeate neurofibroma tissue, mediate key mitogenic signals that contribute to vascular ingrowth, collagen deposition, and tumor growth. Thus, the plexiform neurofibroma microenvironment involves a tumor/stromal interaction with the hematopoietic system that depends, at the molecular level, on a stem cell factor/c-kit-mediated signaling axis. These observations parallel findings in other NF1 disease manifestations and are clearly relevant to medical management of these neurofibromas.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22077553      PMCID: PMC3694738          DOI: 10.1146/annurev-pathol-011811-132441

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  144 in total

1.  Comprehensive NF1 screening on cultured Schwann cells from neurofibromas.

Authors:  Ophélia Maertens; Hilde Brems; Jo Vandesompele; Thomas De Raedt; Ine Heyns; Thorsten Rosenbaum; Sofie De Schepper; Anne De Paepe; Geert Mortier; Sandra Janssens; Frank Speleman; Eric Legius; Ludwine Messiaen
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

2.  Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.

Authors:  Da Yong Lee; Tu-Hsueh Yeh; Ryan J Emnett; Crystal R White; David H Gutmann
Journal:  Genes Dev       Date:  2010-09-28       Impact factor: 11.361

Review 3.  Therapy for plexiform neurofibromas in children with neurofibromatosis 1: an overview.

Authors:  Roger J Packer; Tena Rosser
Journal:  J Child Neurol       Date:  2002-08       Impact factor: 1.987

4.  Mast cells--their presence and ultrastructural characteristics in peripheral nerve tumors.

Authors:  A Pineda
Journal:  Arch Neurol       Date:  1965-10

5.  Double inactivation of NF1 in tibial pseudarthrosis.

Authors:  David A Stevenson; Holly Zhou; Shadi Ashrafi; Ludwine M Messiaen; John C Carey; Jacques L D'Astous; Stephen D Santora; David H Viskochil
Journal:  Am J Hum Genet       Date:  2006-05-10       Impact factor: 11.025

6.  Mast-cell stabilization to decrease neurofibroma growth. Preliminary experience with ketotifen.

Authors:  V M Riccardi
Journal:  Arch Dermatol       Date:  1987-08

7.  Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation.

Authors:  Yuan Zhu; Takayuki Harada; Li Liu; Mark E Lush; Frantz Guignard; Chikako Harada; Dennis K Burns; M Livia Bajenaru; David H Gutmann; Luis F Parada
Journal:  Development       Date:  2005-12       Impact factor: 6.868

Review 8.  The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others.

Authors:  S J Galli; M Tsai; B K Wershil
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

Review 9.  The neurofibromatosis type 1 gene and its protein product, neurofibromin.

Authors:  D H Gutmann; F S Collins
Journal:  Neuron       Date:  1993-03       Impact factor: 17.173

10.  Angiogenic and invasive properties of neurofibroma Schwann cells.

Authors:  S Sheela; V M Riccardi; N Ratner
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

View more
  28 in total

1.  Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Authors:  Michael J Ferguson; Steven D Rhodes; Li Jiang; Xiaohong Li; Jin Yuan; Xianlin Yang; Shaobo Zhang; Saeed T Vakili; Paul Territo; Gary Hutchins; Feng-Chun Yang; David A Ingram; D Wade Clapp; Shi Chen
Journal:  Pediatr Blood Cancer       Date:  2015-09-16       Impact factor: 3.167

2.  Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1

Authors:  Julie A Mund; SuJung Park; Abbi E Smith; Yongzheng He; Li Jiang; Eric Hawley; Michelle J Roberson; Dana K Mitchell; Mohannad Abu-Sultanah; Jin Yuan; Waylan K Bessler; George Sandusky; Shi Chen; Chi Zhang; Steven D Rhodes; D Wade Clapp
Journal:  J Biol Chem       Date:  2020-05-29       Impact factor: 5.157

3.  Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors.

Authors:  Marjorie Carlson; Adrienne L Watson; Leah Anderson; David A Largaespada; Paolo P Provenzano
Journal:  J Biomed Opt       Date:  2017-11       Impact factor: 3.170

4.  Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.

Authors:  Michael J Fisher; Chie-Schin Shih; Steven D Rhodes; Amy E Armstrong; Pamela L Wolters; Eva Dombi; Chi Zhang; Steven P Angus; Gary L Johnson; Roger J Packer; Jeffrey C Allen; Nicole J Ullrich; Stewart Goldman; David H Gutmann; Scott R Plotkin; Tena Rosser; Kent A Robertson; Brigitte C Widemann; Abbi E Smith; Waylan K Bessler; Yongzheng He; Su-Jung Park; Julie A Mund; Li Jiang; Khadijeh Bijangi-Vishehsaraei; Coretta Thomas Robinson; Gary R Cutter; Bruce R Korf; Jaishri O Blakeley; D Wade Clapp
Journal:  Nat Med       Date:  2021-01-13       Impact factor: 53.440

5.  Clinical Images: Imaging Manifestations of Orbital Neurofibromatosis Type 1.

Authors:  James M Milburn; Carlos R Gimenez; Elizabeth Dutweiler
Journal:  Ochsner J       Date:  2016

6.  Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis.

Authors:  Chung-Ping Liao; Reid C Booker; Jean-Philippe Brosseau; Zhiguo Chen; Juan Mo; Edem Tchegnon; Yong Wang; D Wade Clapp; Lu Q Le
Journal:  J Clin Invest       Date:  2018-05-21       Impact factor: 14.808

7.  The plexiform neurofibroma microenvironment.

Authors:  Feng-Chun Yang; Karl Staser; D Wade Clapp
Journal:  Cancer Microenviron       Date:  2012-07-24

8.  Partial Blindness to Submicron Topography in NF1 Haploinsufficient Cultured Fibroblasts Indicates a New Function of Neurofibromin in Regulation of Mechanosensoric.

Authors:  D Kaufmann; J Hoesch; Y Su; L Deeg; K Mellert; J P Spatz; R Kemkemer
Journal:  Mol Syndromol       Date:  2012-09-27

9.  Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.

Authors:  Chao Zhang; Prabha N Ibrahim; Jiazhong Zhang; Elizabeth A Burton; Gaston Habets; Ying Zhang; Ben Powell; Brian L West; Bernice Matusow; Garson Tsang; Rafe Shellooe; Heidi Carias; Hoa Nguyen; Adhirai Marimuthu; Kam Y J Zhang; Angela Oh; Ryan Bremer; Clarence R Hurt; Dean R Artis; Guoxian Wu; Marika Nespi; Wayne Spevak; Paul Lin; Keith Nolop; Peter Hirth; Greg H Tesch; Gideon Bollag
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

Review 10.  The role of stem cells in benign tumors.

Authors:  Haiyan Qin; Dongyu Bao; Xin Tong; Qingang Hu; Guowen Sun; Xiaofeng Huang
Journal:  Tumour Biol       Date:  2016-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.